Diarrhoea Predominant Irritable Bowel Syndrome Completed Phase 4 Trials for Eluxadoline (DB09272)

Also known as: Diarrhea-predominant Irritable Bowel Syndrome / IBS, Diarrhea Predominant / Irritable Bowel Syndrome With Diarrhea / Diarrhea Predominant Irritable Bowel Syndrome / Diarrhea- Predominant Irritable Bowel Syndrome / Diarrhea Dominant Irritable Bowel Syndrome / Irritable bowel syndrome with diarrhea (disorder) / Irritable bowel syndrome without diarrhea / Irritable colon / Colitis mucous / Mucous colitis / Colon spastic / Spastic colon / Irritable colon syndrome / Functional bowel syndrome / Irritable bowel / Irritable bowel syndrome / Irritable colon (disorder)

IndicationStatusPhase
DBCOND0075933 (Diarrhoea Predominant Irritable Bowel Syndrome)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02959983Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide UseTreatment
NCT03441581Eluxadoline Bile Acid Malabsorption (BAM) StudyTreatment